Management of Outpatient Warfarin Therapy amid COVID-19 Pandemic: A Practical Guide.

Compared with standard monitoring, those who used self-monitoring and/or self-adjusted dosing had the following clinical outcomes over a follow-up period of 3–57 months: significantly fewer thromboembolic events (relative risk [RR] 0.58; 95% confidence interval [CI] 0.45–0.75), no difference in major or minor bleeding events (RR 0.95; 95% CI 0.8–1.12 and RR 0.97; 95% CI 0.67–1.41, respectively), and a nonsignificant trend toward reduced mortality (RR 0.85; 95% CI 0.71–1.01).

also in 5,406 other papers